You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Peramivir: A New Drug for Influenza

Martin, Andrew R. MD*; Collins, Curtis D. PharmD, MS*; Otto, Michael MD†; Malani, Anurag MD†; Cinti, Sandro MD*‡

Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e3181f5e967
Review Articles

On June 11, 2009, the World Health Organization declared the first influenza pandemic in more than 40 years. In less than 2 months, the novel 2009 H1N1 influenza A virus had spread from Mexico and the United States to many other countries of the world. Oseltamavir and zanamivir have been used to treat hospitalized and at-risk patients infected with 2009 H1N1 influenza A infection. On October 23, 2009, the Food and Drug Administration issued and Emergency Use Administration for peramivir, an unapproved neuraminidase inhibitor, allowing the drug to be administered to adult and pediatric patients with suspected or confirmed cases of H1N1 influenza A virus. Patients had to have either a refractory case and/or could not tolerate oral or inhaled antiviral medications. This article will review the mode of action, pharmacokinetics and pharmacodynamics, clinical effectiveness, adverse events, and resistance pattern of peramivir and will summarize the Emergency Use Administration issued by the Food and Drug Administration.

Author Information

From the *University of Michigan Hospital and Health Systems; †St Joseph Mercy Hospital System and ‡Veteran's Affairs Ann Arbor Hospital System, Ann Arbor, MI.

Correspondence to: Sandro Cinti, MD, Veteran's Affairs Ann Arbor Health Systems, 2215 Fuller Rd, Ann Arbor, MI 48105. E-mail:

The authors have no funding or conflicts of interest to disclose.

© 2011 Lippincott Williams & Wilkins, Inc.